Introduction {#s1}
============

Receptor tyrosine kinases (RTKs) signal through a shared set of intracellular pathways, including extracellular signal-related kinase (ERK) and phosphatidylinositol 3-kinase (PI3K), yet the in vivo functions directed by different RTKs can be quite distinct, raising the question of how specific cellular responses are elicited ([@bib30]). Several models have been put forth to explain how RTKs encode specificity ([@bib23]; [@bib49]; [@bib44]; [@bib59]). In concept, distinct responses may be encoded by modulation of individual pathways downstream of receptor activation, with each pathway regulating a specific outcome. Alternatively, many cellular responses may require integration from multiple input pathways, and signal specificity could arise from this unique combination of pathways. Analysis of mice harboring point mutations to disrupt binding of specific effector proteins to RTKs suggests both these models may apply in vivo; platelet-derived growth factor (PDGF) Receptor α (*Pdgfra*) mutants display effector-specific phenotypes in line with the former model ([@bib27]), but PDGF Receptor β (*Pdgfrb*) mediated outcomes require combined output across multiple pathways, consistent with the latter model ([@bib52]). In addition, quantitative differences in the duration and magnitude of signal induction provide an added layer of regulatory complexity ([@bib35]). At the transcriptional level, one outcome of RTK activation is the expression of immediate early genes (IEGs) ([@bib11]; [@bib29]). Studies in cell culture have suggested IEGs constitute a generic readout of RTK activation with minimal specificity at the receptor or intracellular effector level ([@bib15]), but genetic experiments in mice indicate a degree of IEG specificity ([@bib48]). Therefore, a central goal remains to delineate RTK responsive transcriptional programs, identify the key signaling parameters encoding their regulation, and determine how these gene expression profiles dictate cellular decisions.

Many components of RTK signaling play important roles in mammalian craniofacial development ([@bib3]; [@bib41]; [@bib17]). In particular, PDGF and FGF signaling are both essential for midface development. In mice, loss of *Pdgfra* ([@bib50]) or its ligands *Pdgfa* and *Pdgfc* ([@bib14]) results in facial clefting, and mice harboring a mutation abrogating PI3K binding to PDGFRα mirror these craniofacial phenotypes, implicating PI3K as the main effector of PDGFRα signaling ([@bib27]). In addition, both *Pdgfra* (*Wnt1-Cre*; *Pdgfra*^*fl/fl*^) ([@bib53]) and FGF receptor 1 (*Wnt1-Cre; Fgfr1*) ([@bib56]; [@bib60]) neural crest conditional mutants exhibit cleft face, indicating both pathways are required for normal development of the neural crest derived facial skeleton. At the intracellular pathway level, previous work has implicated ERK as a key effector downstream of FGF signaling ([@bib28]). Furthermore, mutations in both PDGF and FGF signaling have been linked to craniofacial syndromes in humans ([@bib10]; [@bib38]; [@bib45]). Interestingly, chimeric receptor experiments in mice have shown that the intracellular domain of *Fgfr1* cannot compensate for *Pdgfra* during development, suggesting these two receptors transmit biologically distinct signals in vivo ([@bib19]). The midface thus offers a unique opportunity to interrogate the mechanisms of signal specificity between these two RTKs in a developmentally relevant system.

Given the requirement for PDGF and FGF signaling in the development of the neural crest derived midface, we sought to compare the gene expression programs regulated by these two RTKs. The architecture of the transcriptional response to RTK activation consists of three stereotypic waves: an IEG response involving core transcriptional regulators (*Fos*, *Jun*, *Egr*), a delayed response playing a feedback role (phosphatases, RNA-binding proteins), and a late sustained response determining cellular outcome ([@bib1]; [@bib2]). However, the degree of conservation between genes regulated in each wave across different RTK families is unclear. Furthermore, although classic feedback regulators of mitogen-activated protein kinase (MAPK) pathways have been described, such as dual-specificity phosphatases (DUSPs) for ERK and c-Jun N-terminal kinase (JNK) ([@bib31]; [@bib43]), the extent of effector-dependent transcription genome-wide is not well characterized.

In the present work, we compare the transcriptional response to PDGF and FGF signaling in E13.5 mouse embryonic palatal mesenchyme (MEPM) cells. Although both PDGF and FGF are required in the neural crest for craniofacial development, we find distinct transcriptional programs, effector dependencies, and cellular outcomes in response to each RTK. While many genes in the early wave are shared across the two RTKs, FGF induces a quantitatively stronger response than PDGF. In addition, the feedback control provided by the delayed transcriptional wave displays distinct characteristics in response to PDGF and FGF. By exploring the effect of MEK/ERK and PI3K inhibition on these RTK-regulated gene expression profiles, we find PDGF-mediated transcription displays greater PI3K dependence, while FGF-mediated gene expression programs predominantly require ERK activity. This relationship is conserved at the level of cellular outcome, with FGF driving proliferation but PDGF promoting PI3K-dependent differentiation. Finally, we show overlapping domains of PI3K signaling, PDGF target gene expression, and skeletal differentiation during palatogenesis in vivo, a process perturbed in *Fgfr1* conditional mutants. Taken together, our studies suggest unique roles for PDGF and FGF during development of the facial skeleton, and more broadly, demonstrate that distinct transcriptional responses to RTK signaling are encoded through qualitative and quantitative differences in intracellular pathway activation.

Results {#s2}
=======

PDGF and FGF have distinct patterns of effector activation and transcriptional responses in E13.5 MEPMs {#s2-1}
-------------------------------------------------------------------------------------------------------

Since neural crest conditional loss of either *Fgfr1* or *Pdgfra* leads to clefting, we chose to perform RNA-seq on E13.5 MEPMs treated with either PDGFA or FGF1 + heparin to identify the gene expression programs regulated by each signaling pathway ([Figure 1A](#fig1){ref-type="fig"}). MEPMs express many essential markers of the palatal mesenchyme and have been previously used to study responses to many pathways ([@bib7]; [@bib24]; [@bib16]), including PDGF and FGF ([@bib57]). We performed RNA-seq at 1 and 4 hr following ligand treatment in order to characterize both the early and late responses to PDGF and FGF signaling ([Supplementary File 1](#SD1-data){ref-type="supplementary-material"}). In the samples submitted for sequencing, both PDGF and FGF induced a robust phospho-ERK (pERK) response at 15 min ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}), and MEPMs generated from *Pdgfra-GFP* ([@bib19]) and *Fgfr1-CFP* (to be described elsewhere) knockin reporter embryos display expression of each receptor at the protein level in all cells ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}), further validating MEPMs as a suitable system to study RTK responses.10.7554/eLife.07186.003Figure 1.FGF and PDGF stimulation result in distinct transcriptional responses.(**A**) Mouse embryonic palatal mesenchyme (MEPM) cells were dissected from E13.5 embryos, passaged twice, and then serum starved overnight prior to stimulation with either PDGFAA or FGF1 + heparin. (**B**) Expression of all genes with FPKM (fragments per kilobase of exon per million reads mapped) \>1 at 1 hr (11,217 genes) and (**B\'**) 4 hr (11,266 genes). Genes colored blue are significantly increased with fibroblast growth factor (FGF) treatment and genes colored red are significantly increased with platelet-derived growth factor (PDGF) treatment. Values plotted on log~2~ scale. (**C**) Fold change (FC) comparison for all differentially expressed (DE) genes at (**C**) 1 hr or (**C\'**) 4 hr (compared to serum starved sample) shows high correlation between the transcriptional response to each growth factor at 1 hr but low correlation at 4 hr. (**D**) Protein--protein interaction (PPI) network for all genes upregulated at 1 hr contains many classic immediate early genes (such as AP-1 components, *Myc*, and *Srf*). Genes are colored based on their primary reported role in transcriptional regulation (22, 23), with orange squares representing activators and gray circles representing repressors. (**E**) FC (compared to untreated sample) for selected genes upregulated at 1 hr. Genes in bold are induced \>1.5-fold in response to the indicated growth factor. Although both PDGF and FGF regulate many shared targets, the induction in response to FGF exhibits greater magnitude (*Fos*, *Fosb*, *Junb*, *Atf3*, *Egr1*, *Egr2*) and longer duration (*Fos*, *Fosb*, *Jun*, *Junb*, *Egr1*, *Egr2*).**DOI:** [http://dx.doi.org/10.7554/eLife.07186.003](10.7554/eLife.07186.003)10.7554/eLife.07186.004Figure 1---figure supplement 1.Characterization of E13.5 MEPMs and transcriptional response to PDGF and FGF signaling.(**A**) In the samples submitted for RNA-seq, both PDGF and FGF induce robust pERK responses at 15 minutes. (**B**) MEPMs derived from either *Pdgfra-GFP* or *Fgfr1-CFP* knockin reporter embryos express each receptor in all cells, confirming MEPMs are a homogenous cell population at the level of PDGF and FGF receptor expression. (**C**) Principal component analysis (PCA) reveals distinct responses to PDGF and FGF signaling, with the first principal component (51.29% of variance) segregating conditions based on ligand treatment and the second principal component (12.61% of variance) separating samples based on duration of stimulation. (**D**) Gene ontology analysis (molecular function) on genes induced at 1 hr reveals an overrepresentation of transcription factors and MAP kinase phosphatases (DUSPs). (**E**) Validation of selected transcription factors by qPCR confirms greater magnitude and duration of induction by FGF compared to PDGF.**DOI:** [http://dx.doi.org/10.7554/eLife.07186.004](10.7554/eLife.07186.004)

We first plotted the expression of all genes with FPKM (fragments per kilobase of exon per million reads mapped) values \>1 at both 1 hr ([Figures 1B](#fig1){ref-type="fig"} and 4 hr ([Figure 1B\'](#fig1){ref-type="fig"}); although only a small number of genes are differentially regulated between the 1-hr PDGF and 1-hr FGF samples (Cuffdiff q \< 0.1, [Supplementary File 2](#SD2-data){ref-type="supplementary-material"}; [@bib54]), the difference in the response to these two growth factors is much greater at 4 hr. Consistent with this observation, visualization of all replicates by principal component analysis (PCA) ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}) revealed that the 1-hr PDGF and 1-hr FGF samples cluster together, but the 4-hr FGF replicates are distinctly separate from the 4-hr PDGF samples. Comparing the stimulated MEPMs to untreated cells, genes differentially regulated at 1 hr by either PDGF or FGF ([Supplementary File 2](#SD2-data){ref-type="supplementary-material"}) show high correlation (r^2^ = 0.8173, [Figure 1C](#fig1){ref-type="fig"}), but by 4 hr, the two RTK signals are divergent (r^2^ = 0.2881, [Figure 1C\'](#fig1){ref-type="fig"}). In addition, the genes regulated by PDGF at 1 hr (n = 40) form a subset of those genes regulated by FGF at 1 hr (n = 159), further highlighting the similarity within the early response to both growth factors. Gene ontology analysis ([@bib22]) of the genes induced at 1 hr revealed an enrichment of transcription factors and MAP kinase phosphatases downstream of both RTKs ([Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}, p \< 0.001), similar to previous descriptions of the response to RTK activation ([@bib1]; [@bib2]). To better visualize the organization of these targets, we constructed a protein--protein interaction (PPI) network from the genes regulated at 1 hr; in constructing this network, we only included direct interactions between proteins (path length = 1) and excluded predicted interactions ([@bib4]; [@bib9]). The resulting network contains 25 upregulated genes (out of 113 total induced genes), including many classic components of the IEG response, such as activator protein-1 (AP-1) subunits (*Fos*, *Jun*) and their regulators (*Zfp36*, *Atf3*) as well as *Myc*, *Egr1-4*, and *Srf* ([Figure 1D](#fig1){ref-type="fig"}). Closer inspection revealed that many shared target genes within this network are regulated to both a stronger magnitude and longer duration following FGF treatment compared to PDGF treatment ([Figure 1E](#fig1){ref-type="fig"}). Indeed, *Fos*, *Fosb*, *Jun*, and *Junb* all exhibit differences in signal magnitude and/or duration in response to FGF, as validated by qPCR ([Figure 1---figure supplement 1E](#fig1s1){ref-type="fig"}). In sum, the two RTKs induce a similar gene expression profile at 1 hr ([Figure 1C](#fig1){ref-type="fig"}), as evidenced by the high-correlation coefficient and overlap between genes differentially regulated by PDGF and FGF at 1 hr. However, FGF drives a quantitatively stronger early response with many transcription factors showing both a stronger magnitude and greater duration of induction in response to FGF compared to PDGF ([Figure 1E](#fig1){ref-type="fig"}), which may explain in part the divergent gene expression profiles observed at 4 hr.

Differential roles for the delayed transcriptional response in regulation of signaling downstream of FGF and PDGF {#s2-2}
-----------------------------------------------------------------------------------------------------------------

Given the importance of MEK/ERK and PI3K/Akt signaling downstream of these RTKs during development ([@bib27]; [@bib12]; [@bib28]; [@bib16]), we analyzed pERK and pAkt activation following FGF and PDGF stimulation in MEPMs ([Figure 2A](#fig2){ref-type="fig"}). Consistent with the stronger response to FGF treatment in the gene expression data, the FGF-induced pERK response displays both a higher magnitude and longer duration of activation compared to the PDGF-induced pERK signal. In contrast, both FGF and PDGF induce similar patterns of pAkt activation, but the magnitude of the PDGF-pAkt induction is slightly greater. The FGF-pERK signal is apparent up to 6 hr following growth factor treatment ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}), and increasing the dose of PDGFA ligand did not alter the kinetics of pERK activation ([Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}). To better understand differences in the response to PDGF and FGF, we performed gene ontology analysis for the molecular function of genes that are differentially expressed (DE) between 4-hr PDGF treatment and 4-hr FGF treatment ([Figure 2B](#fig2){ref-type="fig"}, p \< 0.001) ([@bib22]). The top results for genes enriched following FGF treatment are sets associated with modulation of signaling, such as protein kinases and GTPase regulators, which may function as activators of Ras to promote MEK/ERK signaling. Transcriptional feedback regulation of RTK signaling is well established, particularly the role of DUSPs providing negative feedback for MAPK signaling ([@bib1]; [@bib31]; [@bib43]). Indeed, many DUSPs (MAPK phosphatases) are induced in response to both PDGF and FGF treatment at 1 hr ([Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}), but FGF alone induces the expression of kinases and GTPase regulators at 4 hr, suggesting a distinct role for the FGF response in regulating MEK/ERK activity. We, thus, performed Western blots in the presence of cycloheximide following both PDGF and FGF treatment to determine the effect of inhibiting protein synthesis (and consequently, the delayed transcriptional response) on ERK activation. Consistent with previous work exploring the role of DUSP-mediated negative feedback ([@bib1]), cycloheximide treatment increased the duration of the PDGF-pERK response ([Figure 2C](#fig2){ref-type="fig"}). However, we observed the opposite effect of cycloheximide treatment on the FGF-pERK response ([Figure 2C\'](#fig2){ref-type="fig"}), suggesting a positive feedforward loop in which FGF induces the expression of kinases and GEFs to modulate the ERK response in addition to activating ERK directly. To further explore the architecture of the late FGF response, we constructed a PPI network from genes increased at 4-hr FGF stimulation compared to 4-hr PDGF treatment. The FGF network ([Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}) contains *Prkca* as a highly connected node, which is interesting given reported roles for protein kinase C (PKC) in facilitating a sustained pERK response ([@bib5]; [@bib47]) as well as its importance downstream of FGF in skeletal development ([@bib38]). We found that inhibition of PKC decreased both the initial pulse and sustained activation of the FGF-mediated pERK response in MEPMs ([Figure 2---figure supplement 1C\'](#fig2s1){ref-type="fig"}), consistent with its potential function as a hub within the FGF response network. In addition, many of the kinases and GEFs transcriptionally regulated by FGF have reported roles in positively modifying MEK/ERK signaling ([Figure 2---figure supplement 1D](#fig2s1){ref-type="fig"}), which may explain in part the residual pERK response to FGF in the presence of PKC inhibition. Collectively, these data support a model in which the balance between positive and negative transcriptional loops is critical for determining patterns of pERK response to different RTKs ([Figure 2D](#fig2){ref-type="fig"}).10.7554/eLife.07186.005Figure 2.The delayed transcriptional response provides differential regulation of pERK duration in response to FGF and PDGF signaling.(**A**) Signaling time course shows a more robust phospho-ERK (pERK) response to FGF (blue) than PDGF (red) and a similar pAkt response to both growth factors. (**B**) Gene ontology analysis (molecular function) of genes DE between the 4-hr PDGF and 4-hr FGF conditions indicates enrichment for kinases and GTPase regulators in response to FGF signaling. (**C**) Cycloheximide treatment has opposite effects on pERK duration following (**C**) PDGF and (**C\'**) FGF stimulation, indicating the delayed transcriptional response (dependent on protein synthesis and thus inhibited by cycloheximide) can provide both negative and positive signals to modulate pERK kinetics. (**D**) Model depicting loops that regulate the duration of the pERK wave in response to receptor tyrosine kinase (RTK) signaling includes both negative (dual-specificity phosphatases \[DUSPs\]) and positive (kinases, GEFs) components from the delayed transcriptional response. Western blot quantification plotted as mean ± SEM, n = 3.**DOI:** [http://dx.doi.org/10.7554/eLife.07186.005](10.7554/eLife.07186.005)10.7554/eLife.07186.006Figure 2---figure supplement 1.Signaling kinetics and organization of the late transcriptional response in response to PDGF and FGF treatment.(**A**) Long timecourse of PDGF and FGF treatment followed by Western blot for pERK and pAkt shows the FGF mediated pERK response persists up to 6 hours following growth factor stimulation. (**B**) The duration of the pERK response to PDGFA treatment does not change with increasing ligand dosage, indicating 30 ng/mL is a saturating dose for pERK duration. (**C**) PPI network constructed from genes differentially expressed at 4 hours following FGF treatment reveals *Prkca* as a highly connected node, suggesting Protein Kinase C as a regulator of the pERK driven FGF response. (**C\'**) Inhibition of PKC abolishes both the initial pulse and sustained wave of pERK in response to FGF treatment. (**D**) Many candidate kinases and GEFs, such as *Prkca* ([@bib5]), *Stk40* ([@bib31a]), *Trib1* ([@bib26a]), *Sgk1* ([@bib60a]), *Vav3* ([@bib7a]), and *Bcar3* ([@bib18a]), have reported roles in positively modifying MEK/ERK signaling. *Prkca***DOI:** [http://dx.doi.org/10.7554/eLife.07186.006](10.7554/eLife.07186.006)

The FGF transcriptional response is primarily MEK/ERK dependent, while the PDGF response shows greater PI3K usage {#s2-3}
-----------------------------------------------------------------------------------------------------------------

The differences in signaling pathway activation following PDGF and FGF stimulation led us to consider how inhibition of these pathways affected the two RTK-mediated transcriptional programs. Thus, we analyzed the effector dependence of the transcriptional response by performing RNA-seq in cells stimulated with either PDGF or FGF in the presence of PD325901 (MEK inhibitor) or LY294002 (PI3K inhibitor) ([Supplementary File 1](#SD1-data){ref-type="supplementary-material"}). PCA on all thirteen sequenced conditions ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}) segregates the samples based on growth factor treatment along PC1 (44.57% of the variance) and on inhibitor treatment along PC2 (17.72% of the variance). Similarly, the correlation matrix for all sampled replicates mimics the PCA, with the 4 hr FGF and 4 hr FGF + LY showing a gene expression profile distinct from all other samples ([Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}). We next directly tested the effect of pathway inhibition on both the shared gene expression program induced by the two RTKs at 1 hr (113 genes total) and the genes regulated between FGF and PDGF treatment at 4 hr. Globally, FGF target genes show greater MEK/ERK dependence than PI3K dependence, while PDGF responsive genes exhibit the opposite relationship ([Supplementary File 3](#SD3-data){ref-type="supplementary-material"}) mirroring the reported signaling requirements for each RTK. This trend is apparent at 1 hr ([Figure 3A, A\'](#fig3){ref-type="fig"}) and striking for genes DE at 4 hr, where 52% of FGF responsive genes are MEK/ERK dependent ([Figure 3B](#fig3){ref-type="fig"}) but only 22% were PI3K dependent ([Figure 3B\'](#fig3){ref-type="fig"}). This dependence is inverted for PDGF, where 9% are MEK/ERK dependent ([Figure 3C](#fig3){ref-type="fig"}) but 28% are PI3K dependent ([Figure 3C\'](#fig3){ref-type="fig"}). Strikingly, MEK inhibition increases the expression of PDGF targets ([Figure 3C](#fig3){ref-type="fig"}) but not FGF targets ([Figure 3B](#fig3){ref-type="fig"}), while PI3K inhibition increases the expression of FGF responsive genes ([Figure 3A\', B\'](#fig3){ref-type="fig"}), suggesting the FGF-ERK and PDGF-PI3K relationships are important for both gene induction and repression. These intracellular pathway dependencies are independent of the magnitude of induction/repression, as varying the FC threshold did not affect the PDGF-PI3K or FGF-ERK relationships ([Figure 3---figure supplement 1C, D\'](#fig3s1){ref-type="fig"}).10.7554/eLife.07186.007Figure 3.FGF and PDGF transcriptional responses exhibit differential usage of intracellular pathways.(**A**) Volcano plots visualizing the effect of (**A**) MEK (Mitogen/Extracellular signal-regulated kinase) inhibition and (**A\'**) phosphatidylinositol 3-kinase (PI3K) inhibition on the shared set of 113 genes upregulated at 1 hr reveal that FGF (blue points) shows increased dependence on MEK/extracellular signal-related kinase (ERK) signaling, while PDGF (red points) utilizes PI3K to a greater degree. X-axis plotted as log~2~(\[1 hr ligand + inhibitor\]/\[1 hr ligand\]). (**B**) Genes with increased expression at 4-hr FGF treatment show higher dependence on (**B**) MEK/ERK activity compared to (**B\'**) PI3K. (**C**) In contrast, genes with increased expression at 4-hr PDGF treatment show greater usage of (**C\'**) PI3K compared to (**C**) MEK/ERK. X-axis plotted as log~2~(\[4 hr ligand + inhibitor\]/\[4 hr ligand\]). Data analyzed using two sample t-test, and genes at p \< 0.1 are colored significant. Black points represent genes not significant at this threshold in all plots. (**D**) A core set of MEK/ERK (20 genes) and PI3K (16 genes) are dependent on these pathways downstream of both PDGF and FGF. (**D\'**) A minority of genes can be activated through either MEK/ERK or PI3K signaling in response to PDGF or FGF, indicating a degree of plasticity in intracellular pathway usage. (**E**) Scatter plot comparing effect of MEK/ERK and PI3K inhibition on all 4 hr DE genes reflects FGF-ERK and PDGF-PI3K dependencies. Data plotted as log~2~(\[4 hr ligand + inhibitor\]/\[4 hr ligand\]) and capped at ±5 for visualization. (**E\'**) 52% of FGF target genes at 4 hr are repressed by MEK/ERK inhibition, while 28% of PDGF responsive genes are repressed by PI3K inhibition. Interestingly, 12% of genes are repressed by MEK/ERK inhibition and 'superinduced' by PI3K inhibition, indicating crosstalk between these pathways. Furthermore, 43% of PDGF responsive genes and 34% of FGF responsive genes are not significantly affected by either inhibitor, which suggests either combinatorial requirement of MEK and PI3K or alternate intracellular pathways drive expression of these genes.**DOI:** [http://dx.doi.org/10.7554/eLife.07186.007](10.7554/eLife.07186.007)10.7554/eLife.07186.008Figure 3---figure supplement 1.RTK target genes show distinct patterns of effector dependence in a threshold-independent manner.(**A**) PCA of all 13 conditions highlights effects of ligand stimulation and inhibitor treatment, with the first principal component (44.57% of variance) segregating conditions based on ligand treatment and the second principal component (17.72% of variance) separating samples based on inhibitor treatment. (**B**) Correlation matrix comparing the effect of inhibitor treatment across all PDGF and FGF stimulated replicates indicates distinct effects for PD and LY treatment. (**C**) The FGF-ERK and PDGF-PI3K relationships occur independently of FC threshold selection, indicating there is not a specific effect for ERK or PI3K inhibition based on magnitude. The number of genes repressed in the FGF-PD condition is greater than the number of the genes in the FGF-LY condition for all thresholds, while PDGF shows greater PI3K dependence than FGF, both MEK/ERK and PI3K signaling are utilized by PDGF across all thresholds. A subset of genes show significant 'superinduction' in the presence of inhibitor treatment, particularly for PI3K inhibition downstream of FGF. Each point on the x-axis represents a different threshold, and the value on the y-axis indicates the number of genes with a log~2~ ratio greater than that threshold. (**D**) The FGF-ERK and PDGF-PI3K relationships at 4 hr are also conserved independently of FC threshold selection. For any given threshold, (**D**) PI3K inhibition represses more PDGF target genes and MEK/ERK inhibition induces more PDGF target genes. Similarly, (**D\'**) MEK/ERK inhibition has a stronger repressive effect on FGF target genes than PI3K inhibition at all thresholds.**DOI:** [http://dx.doi.org/10.7554/eLife.07186.008](10.7554/eLife.07186.008)

We then considered the degree of overlap between ERK and PI3K targets. At 1 hr, many shared target genes show similar ERK or PI3K dependence, possibly constituting a core pathway specific gene set ([Figure 3D](#fig3){ref-type="fig"}). On the other hand, cross-comparison of PI3K- and ERK-dependent genes reveals some overlap ([Figure 3D\'](#fig3){ref-type="fig"}), underscoring a degree of plasticity in pathway usage downstream of different RTKs. When directly comparing the effect of MEK and PI3K inhibition at 4 hr ([Figure 3E](#fig3){ref-type="fig"}), the crosstalk between FGF targets is particularly striking, as a large number of genes repressed by MEK inhibition were regulated (both positively and negatively) by PI3K inhibition. Furthermore, while 23% of PDGF targets are specifically PI3K dependent, only 5% of FGF targets are repressed by PI3K alone ([Figure 3E\'](#fig3){ref-type="fig"}). Instead, many FGF-PI3K targets are also repressed by MEK inhibition (77%), and conversely, a number of FGF-ERK targets are induced by PI3K inhibition (23%), indicating the effect of PI3K inhibition downstream of FGF involves crosstalk with ERK signaling.

Inhibition of intracellular effector activation leads to induction of alternate signaling pathways {#s2-4}
--------------------------------------------------------------------------------------------------

We were intrigued by the subset of genes exhibiting significantly increased expression ('superinduction') following inhibitor treatment at both 1 and 4 hr. Both RTKs show increased *Jun* expression in response to PD325901, while FGF and LY294002 treatment upregulates many classic ERK targets such as *Fos*, *Fosb*, and *Dusp6* ([Supplementary File 3](#SD3-data){ref-type="supplementary-material"}), suggesting this 'superinduction' may reflect compensatory activation of other intracellular pathways. Many such examples of crosstalk between ERK and PI3K have been documented ([@bib36]). Thus, we assayed the activation of these pathways following MEK inhibition with PD325901 and PI3K inhibition with LY294002. We found striking induction of pJNK upon pERK inhibition by PD325901 downstream of both FGF ([Figure 4A](#fig4){ref-type="fig"}) and PDGF ([Figure 4B](#fig4){ref-type="fig"}) stimulation. Interestingly, a moderate change in pAkt induction following PDGF treatment and MEK inhibition seems apparent, although this induction was not observed at the dose used for the RNA-seq experiment (1 μM PD325901). Next, we investigated the effect of PI3K inhibition with LY294002. We found that FGF-mediated pERK induction increased with LY294002 treatment ([Figure 4A\'](#fig4){ref-type="fig"}), but PDGF treatment did not produce this increase in pERK signal ([Figure 4B\'](#fig4){ref-type="fig"}), consistent with changes observed at the level of target gene expression. At the inhibitor doses used in the RNA-seq experiment (1 μM PD325901, 10 μM LY294002), both PDGF and FGF significantly induce JNK activation in the presence of MEK inhibition, while only FGF activates ERK when PI3K is inhibited ([Figure 4C, C\'](#fig4){ref-type="fig"}). Finally, we performed qPCR for a subset of target genes to confirm their response to pathway inhibition. *Fos*, *Fosb*, and *Junb* exhibit 'superinduction' downstream of FGF specifically in response to PI3K inhibition, confirming these genes are indeed MEK/ERK dependent and providing further evidence that LY294002-mediated induction of pERK can drive transcriptional changes ([Figure 4D](#fig4){ref-type="fig"}). Similarly, *Jun* is 'superinduced' in the presence of PD325901 downstream of both RTKs. There is a modest increase in *Jun* induction following FGF treatment with PI3K inhibition, likely reflecting the compensatory induction of pERK in this condition and consequent crosstalk between ERK and JNK signaling. In addition, *Fos* induction is increased with LY294002 treatment even in the absence of growth factor, which may reflect a degree of growth factor independent crosstalk between PI3K and ERK. However, this effect synergizes with ligand treatment, indicating this compensation across intracellular pathways is at least partially dependent on receptor activation.10.7554/eLife.07186.009Figure 4.Inhibition of effector activation results in compensatory induction of alternate signaling pathways detectable in the transcriptional response.(**A**) PD325901 dose response Western blots reveal induction of pJNK as pERK is progressively inhibited downstream of FGF signaling. (**A\'**) Similarly, LY294002 dose response Western blots reveal increased pERK signal as pAkt is inhibited. (**B**) Inhibitor dose response Western blots in response to PDGF signaling show activation of c-Jun N-terminal kinase (JNK) in response to MEK/ERK inhibition but (**B\'**) no activation of ERK following PI3K inhibition. (**C**) Quantification of effector activation in response to FGF (blue) or PDGF (red) at the doses used in the RNA-seq experiment reflects (**C**) increased pJNK activation when MEK/ERK signaling is inhibited and (**C\'**) increased pERK induction when PI3K activity is blocked. Data plotted as mean ± SEM, n = 3 and compared using two sample, unpaired t-test to baseline of 100% (no change). \*p \< 0.05; \*\*p \< 0.001. (**D**) Gene expression reflects the crosstalk observed at the signaling level, as verified by qPCR for selected target genes. Canonical ERK targets such as *Fos*, *Fosb*, and *Junb* are 'superinduced' upon LY treatment, while the JNK target *Jun* is 'superinduced' with PD treatment. Interestingly, a degree of 'superinduction' is observed in the presence of inhibitor prior to growth factor addition, which may reflect RTK-independent crosstalk between intracellular pathways. Data plotted as mean ± SEM, n = 3.**DOI:** [http://dx.doi.org/10.7554/eLife.07186.009](10.7554/eLife.07186.009)

FGF drives MEK/ERK-dependent cell proliferation, and PDGF promotes PI3K-dependent cell differentiation {#s2-5}
------------------------------------------------------------------------------------------------------

We next investigated the functional consequence of these differential effector activation patterns and transcriptional programs in response to PDGF and FGF signaling. Gene ontology for biological processes ([@bib22]) enriched in genes differentially regulated by PDGF and FGF at 4 hr revealed an FGF-mediated proliferation program and a PDGF-regulated differentiation circuit ([Figure 5A](#fig5){ref-type="fig"}, p \< 0.001). Interestingly, we also observed enrichment for regulators of Wnt signaling in the 4-hr PDGF condition, consistent with reports of antagonism between Wnt and FGF as regulating the balance between differentiation and proliferation in skeletal development ([@bib34]). We further identified a set of differentiation genes (*Id1*, *Id2*, *Id3*, *Mef2c*, *Atoh8*) in the PPI network constructed from genes regulated by PDGF treatment at 4 hr ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}) and confirmed these genes by qPCR ([Figure 5---figure supplement 1A\'](#fig5s1){ref-type="fig"}). In line with PDGF directing a skeletal differentiation program, the *Id* genes ([@bib33]; [@bib25]) and *Mef2c* ([@bib58]) are required for craniofacial skeleton development in vivo. In addition, mouse genome informatics mammalian phenotype analysis to determine overrepresented mouse phenotypes ([@bib8]) identifies abnormal craniofacial bone development as the most enriched phenotype in the 4-hr PDGF target genes ([Figure 5---figure supplement 1B, B\'](#fig5s1){ref-type="fig"}). Plotting the expression of these FGF-proliferation and PDGF-differentiation genes emphasizes the distinct responses of these gene sets to these two growth factors ([Figure 5B](#fig5){ref-type="fig"}). Furthermore, many proliferation genes are reduced upon MEK inhibition and induced upon PI3K inhibition, while the opposite is apparent for differentiation genes, consistent with the FGF-ERK and PDGF-PI3K dependencies observed globally at the transcriptional level.10.7554/eLife.07186.010Figure 5.Distinct cellular outcomes are specified in response to PDGF and FGF signaling.(**A**) Gene ontology analysis of genes DE between the 4-hr FGF and 4-hr PDGF conditions shows enrichment for regulators of cell proliferation in genes upregulated by FGF treatment. In contrast, genes implicated in skeletal differentiation are overrepresented in the genes more highly expressed following PDGF treatment (**B**) Genes associated with cell proliferation are strongly upregulated by FGF treatment, while genes associated with cell differentiation are increased following PDGF stimulation. In addition, MEK inhibition represses many proliferation genes but induces differentiation genes, while PI3K inhibition has the opposite effect. Genes ordered by decreasing ratio of FGF:PDGF expression. (**C**) FGF induces a significantly more robust proliferation response than PDGF in MEPMs, although PDGF does promote a modest response compared to starved cells (0.1% FBS). Quantification plotted as mean ± SEM, n = 3. Two tailed, unpaired t-test: \*p \< 0.05; \*\*p \< 0.005 (**D**) PDGF, but not FGF, treatment promotes alkaline phosphatase (AP) (osteoblast marker) positive cells. Furthermore, PD treatment drives AP staining, while LY treatment abolishes AP staining independent of growth factor stimulation. AP staining performed 8 hr following ligand treatment.**DOI:** [http://dx.doi.org/10.7554/eLife.07186.010](10.7554/eLife.07186.010)10.7554/eLife.07186.011Figure 5---figure supplement 1.PDGF-mediated differentiation responses exhibit a preference for PI3K signaling, while FGF-mediated effects on proliferation show greater MEK/ERK dependence.(**A**). The PPI network for the genes upregulated at 4 hr following PDGF treatment shows a concentration of genes involved in controlling cell differentiation (*Id1*, *Id2*, *Id3*, *Atoh8*, *Mef2c*), suggesting a PDGF-mediated differentiation program in MEPMs. (**A\'**) Validation of genes in the PDGF target PPI network by qPCR confirmed these genes are increased following PDGF stimulation compared to FGF treatment. (**B**) Genes with higher expression at 4 hr following PDGF treatment show enrichment for craniofacial and skeletal phenotypes in mice, consistent with the enrichment for differentiation genes in the 4-hr PDGF condition. The top 10 terms are shown, and selected genes with craniofacial phenotypes are listed. (**B\'**) Heatmap displaying expression of genes associated with craniofacial phenotypes and exhibiting increased expression at 4 hr PDGF stimulation. Many of these genes show increased expression upon MEK inhibition and decreased expression upon PI3K inhibition, consistent with a PDGF-PI3K-differentiation circuit. (**C**) Crystal violet assay demonstrates that a full FGF response (blue lines) requires both MEK/ERK and PI3K activity, although the effect of MEK/ERK inhibition is significantly greater. In contrast, the PDGF-mediated effect (red lines) on cell viability requires both MEK/ERK and PI3K activity, suggesting these pathways are utilized somewhat equally downstream of PDGF signaling. Data plotted as mean ± SEM, n = 3. (**D**) Cleaved Caspase-3 staining reveals that inhibition of FGF-mediated MEK/ERK signaling leads to significantly greater apoptosis, while both MEK and PI3K inhibition downstream of PDGF signaling leads to cell death. Data plotted as mean ± SEM, with cell percentages quantified across three fields of view for three biological replicates. CC3: Cleaved Caspase-3. \*p \< 0.1; \*\*p \< 0.01.**DOI:** [http://dx.doi.org/10.7554/eLife.07186.011](10.7554/eLife.07186.011)

To directly assay cell proliferation, we performed BrdU labeling at 4 hr following either FGF or PDGF treatment in E13.5 MEPMs; while PDGF induces a modest response compared to serum-starved cells, we found a significantly greater proliferative response to FGF ([Figure 5C](#fig5){ref-type="fig"}). Crystal violet staining for cell viability confirms a greater effect of FGF than PDGF as well as the importance of MEK/ERK activity for this response ([Figure 5---figure supplement 1C](#fig5s1){ref-type="fig"}). Furthermore, the PDGF-dependent effect on cell viability is significantly greater at day 3 compared to the 0.1% fetal bovine serum (FBS) treated cells, underscoring the role of PDGF in cell survival/growth in the absence of other growth factors. We next measured apoptosis following PDGF and FGF treatment in the presence of both inhibitors ([Figure 5---figure supplement 1D](#fig5s1){ref-type="fig"}). Consistent with the cell viability results and phospho-JNK induction patterns, MEK inhibition following FGF stimulation results in a greater increase in apoptosis than inhibition of FGF-mediated PI3K signaling; in contrast, PI3K inhibition has a greater effect than MEK inhibition downstream of PDGF stimulation, although inhibiting either pathway results in increased apoptosis. Finally, we tested cell differentiation by alkaline phosphatase (AP) staining, a marker of osteoblast differentiation ([@bib61]). PDGF-treated MEPMs display a robust AP response, while FGF-treated cells show a striking lack of AP positive cells ([Figure 5D](#fig5){ref-type="fig"}). In addition, MEK/ERK inhibition increases AP staining, but PI3K inhibition represses osteoblast differentiation ([Figure 5D](#fig5){ref-type="fig"}). These experiments suggest the following model: FGF drives cell proliferation and represses cell differentiation in a MEK/ERK-dependent manner, while PDGF facilitates cell differentiation, at the expense of reduced proliferation, in a PI3K-dependent manner.

The FGF repressed, PI3K-dependent differentiation circuit is conserved during mouse craniofacial development {#s2-6}
------------------------------------------------------------------------------------------------------------

Finally, we sought to investigate the FGF-ERK-proliferation and PDGF-PI3K-differentiation axes in vivo. We first examined the expression pattern of *Fgfr1* in relation to *Dusp6* (ERK-specific), *Dusp1* (JNK-specific), and *Dusp10* (JNK-specific) in the E13.5 palate by in situ hybridization ([Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}). Although *Dusp1* and *Dusp10* are primarily epithelial, *Fgfr1* and *Dusp6* are co-expressed in the anterior palatal mesenchyme, consistent with previous work implicating ERK in proliferation within this region ([@bib7]). Similarly, immunohistochemistry (IHC) revealed pERK is scattered in the anterior palatal mesenchyme, with some epithelial staining ([Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"}). However, cell proliferation along the anterior--posterior axis is relatively uniform in the E13.5 palate ([@bib6]), complicating assignment of the observed expression patterns to a spatially restricted proliferation program. We next explored the relationship between PI3K signaling and osteoblast differentiation. Whole mount IHC for pAkt at E13.5 demonstrates expression restricted to the developing upper lip and middle to posterior palate, overlapping with AP in these structures ([Figure 6A](#fig6){ref-type="fig"}). We further assayed the pattern of Runx2 expression ([Figure 6B](#fig6){ref-type="fig"}) in comparison to *Pdgfra*, *Id1*, and *Id3* in the E13.5 palate ([Figure 6B\'](#fig6){ref-type="fig"}), finding shared domains of expression and exclusion in the palate. Taken together, this correlation between PI3K activity, the *Id* genes, and regions of osteoblast differentiation supports the existence of a spatially restricted PDGF-PI3K-differentiation axis.10.7554/eLife.07186.012Figure 6.In vivo correlation and perturbation of the RTK-mediated differentiation program during mouse craniofacial development.(**A**) At E13.5, pAkt and AP domains co-localize in the middle to posterior secondary palate (red arrowhead) as well as in the developing upper lip (open arrowhead). (**B**) Domain of Runx2 (osteoblast marker) expression overlaps with (**B'**) *Pdgfra*, *Id1*, and *Id3* expression in the middle to posterior palate (red arrowhead), with expression excluded along the midline (black arrowhead). (**C**) Frontal sections from neural crest conditional *Fgfr1* mutants (*Wnt1-Cre; Fgfr1*^*fl/fl*^) exhibit increased AP staining in the developing midface at E14.5, supporting an in vivo role for FGF-mediated repression of osteoblast differentiation (red arrowhead) (n = 3). (**D**) FGF and PDGF signaling use different signaling pathways to instruct divergent cellular outcomes. FGF drives cell proliferation and represses cell differentiation in an ERK-dependent manner, consistent with a greater percentage of the FGF target genes being MEK/ERK dependent (50%) than PI3K dependent (20%). In contrast, PDGF promotes cell differentiation in a PI3K-dependent manner, and PDGF target genes show greater PI3K dependence (30%) than MEK/ERK dependence (10%). Furthermore, inhibition of PI3K signaling leads to an FGF specific induction of pERK (green) and consequently increased transcription of ERK targets such as *Fos*, *Fosb*, and *Junb*. On the other hand, MEK/ERK inhibition leads to pJNK induction (orange) and transcription of *Jun*, indicating multiple crosstalk mechanisms across different intracellular pathways in response to RTK activation. PP: primary palate; PS: palatal shelf; T: tongue; UL: upper lip.**DOI:** [http://dx.doi.org/10.7554/eLife.07186.012](10.7554/eLife.07186.012)10.7554/eLife.07186.013Figure 6---figure supplement 1.Patterns of gene expression and pERK activity in the E13.5 palate.(**A**) In situ hybridization for *Fgfr1*, *Dusp6*, *Dusp1*, and *Dusp10* in the E13.5 palate indicates no obvious spatial correlation between receptor expression and putative domains of ERK and JNK activity. *Fgfr1* and *Dusp6* show enrichment in the anterior palatal mesenchyme (red arrowhead) and epithelium (black arrowhead), while *Dusp1* and *Dusp10* expression are primarily epithelial (black arrowhead). (**B**) Immunohistochemistry for pERK reveals broad expression in both the E13.5 anterior palatal mesenchyme (red arrowhead) and epithelium (black arrowhead). E: epithelium; M: mesenchyme; PS: palatal shelf; T: tongue.**DOI:** [http://dx.doi.org/10.7554/eLife.07186.013](10.7554/eLife.07186.013)

In MEPMs, FGF drives proliferation and represses differentiation. One prediction from this observation is that *Fgfr1* mutants would have decreased repression of this program, and consequently, increased differentiation in the midface. We, therefore, performed AP staining on neural crest conditional *Fgfr1* mutants (*Wnt1-Cre; Fgfr1*^*fl/fl*^) at E14.5 to investigate defects in osteoblast differentiation. We observed an increased domain of AP in the maxillary region of *Fgfr1* conditional mutants compared to heterozygous controls ([Figure 6C](#fig6){ref-type="fig"}). Collectively, these results suggest the FGF repressed, PI3K-dependent differentiation program identified in MEPMs is conserved in vivo.

Discussion {#s3}
==========

Our studies show that PDGF and FGF signaling in MEPMs regulate different gene expression programs and phenotypic outputs, with PDGF mainly promoting cell differentiation through PI3K and FGF favoring cell proliferation through ERK. Although the initial wave of gene expression shows high overlap, FGF elicits a quantitatively stronger response in terms of both signal magnitude and duration, which is reinforced by a positive signal from the delayed transcriptional wave in response to FGF but not PDGF. Furthermore, FGF-responsive genes are predominantly ERK dependent, while PDGF targets exhibit greater PI3K dependence genome-wide, relationships mimicked at the level of cellular outcome. Finally, we observed correlation between PDGF-PI3K signaling and osteoblast differentiation at E13.5 as well as increased AP staining in *Fgfr1* mutants, indicating the differentiation circuit repressed by FGF signaling in MEPMs is functional in vivo.

The architecture of the transcriptional response to RTK signaling has been well described as three stereotypic waves: an IEG response, a delayed wave providing feedback control, and a late wave determining cellular outcome ([@bib1]; [@bib2]). In MEPMs, the magnitude and duration of the IEG wave is much stronger in response to FGF compared to PDGF, suggesting one level of specificity may be achieved through quantitative differences in IEG induction. Indeed, transient and sustained pERK induction, resulting in distinct magnitudes of *Fos* mRNA expression, drive binary responses in c-Fos abundance and activity at the protein level ([@bib39]; [@bib40]), delineating one mechanism through which quantitative differences lead to a thresholded 'ON-OFF' response in downstream transcriptional activity. Thus, in addition to the observed PDGF-PI3K and FGF-ERK relationships, distinct patterns of IEG transcription factor expression may also contribute to the divergent gene expression profiles at later time points.

While inhibition of the delayed transcriptional response prolongs the PDGF-pERK wave, the opposite effect is observed on FGF-pERK induction. This result is consistent with the diversity of feedback and feedforward regulation on the RTK response ([@bib2]; [@bib59]). In addition to transcriptional feedback, many other mechanisms, including ligand identity and receptor endocytosis ([@bib18]), contribute toward specifying the signaling response to RTK activation. The complexity of this regulation underscores the intricate balance between positive and negative control systems, and it will be critical to determine how these regulatory mechanisms interact to produce the desired developmental outcomes.

Given the pleiotropic roles of RTKs, a central question involves how a common set of signal transduction modules specifies distinct outcomes. Our study supports a model in which differential intracellular pathway activation is responsible for the distinct transcriptional responses and cellular processes mediated by RTK signaling in MEPMs ([Figure 6D](#fig6){ref-type="fig"}). Pathway activation downstream of a single RTK can be affected by many parameters, such as receptor expression level ([@bib55]; [@bib52]), suggesting that even a single receptor can regulate multiple downstream outputs and transcriptional programs across different contexts. The role of quantitative differences in the pERK response leading to distinct cellular outcomes is well characterized in PC12 neurons ([@bib35]), and the transcriptional response to the proliferative program mediated by sustained pERK activation in 3T3 fibroblasts has been reported ([@bib63]). Building on these studies, the MEPM RNA-seq data provide insight into the differences in gene expression following both transient and sustained pERK induction as well as qualitatively specific target genes downstream of MEK/ERK and PI3K signaling, with the added advantage of profiling these responses within a system requiring these pathways for normal development. It is important to note that mRNA levels alone (as measured by RNA-seq) are not the only level of specificity in the transcriptional response, for example, differential cofactor recruitment can also specify distinct gene expression programs in response to FGF and PDGF signaling ([@bib57]). Further work is necessary to identify the precise mechanisms regulating the activity of individual RTK target genes.

Although we focused on MEK/ERK and PI3K signaling based on their reported roles downstream of PDGF and FGF during development ([@bib27]; [@bib12]), many other intracellular pathways are activated by RTKs, such as JNK, p38, Src, PLCγ, and PKC ([@bib30]). As previously reported in other contexts ([@bib5]; [@bib47]), we found the FGF-pERK induction was dependent on PKC activity, and we further identified crosstalk in the presence of pathway inhibition between ERK, PI3K, and JNK. In addition, a subset of genes (34% FGF, 43% PDGF) are not affected by MEK/ERK or PI3K inhibition, suggesting they either lie downstream of other intracellular pathways or require inhibition of both ERK and PI3K. Thus, while our studies demonstrate PI3K is necessary for differentiation and ERK is necessary for proliferation in MEPMs, the high connectivity across intracellular pathways suggests no single pathway in isolation is sufficient to drive transcriptional responses and cellular outcomes in their entirety. Rather, integrated output from multiple effector pathways likely contributes to the ultimate cellular outcome, and instead of the existence of linear PDGF-PI3K-differentiation and FGF-ERK-proliferation axes, we favor a model in which multiple signaling events converge on PI3K to promote differentiation and ERK to drive proliferation in the midface.

The finding that effector inhibition increased the induction of many RTK target genes was surprising given their presumed primary function as positive effectors of signaling. The 'superinduction' of these transcriptional responses was due at least in part to compensatory activation of other pathways: inhibition of pERK downstream of both RTKs resulted in increased pJNK induction while inhibition of PI3K downstream of FGF, but not PDGF, resulted in increased pERK activation. This observation has implications for both genetic studies in mice and any system in which effector inhibition is used as an experimental or therapeutic agent. First, allelic series experiments in which adaptor binding is abrogated in order to abolish specific effector cascades may result in induction of alternate signaling pathways, complicating assignment of developmental function to a single intracellular pathway. Indeed, mice harboring a PI3K binding site mutation at the PDGFRα locus show increased SHP2 binding and altered pERK activation ([@bib27]). Second, chemical inhibition of these effectors may prime activation of other pathways, facilitating alternate signaling mechanisms and cellular outcomes. Many examples of such crosstalk between ERK and PI3K ([@bib36]; [@bib51]) as well as ERK and JNK ([@bib32]) have been described downstream of RTK signaling in cancer. The MEPM RNA-seq data provide a transcriptional signature for this crosstalk, offering an additional readout to measure activation of these pathways. However, it is important to caution that these responses likely vary based on cellular context, and although the core target genes and effector dependencies may be conserved, extrapolating this framework to other systems requires careful validation.

In comparing our gene expression studies to mouse craniofacial development in vivo, we found co-localization of pAkt and AP in the upper lip and middle to posterior palate at E13.5 as well as overlapping domains of *Runx2* and *Id* gene expression, indicating the PDGF-PI3K axis identified in MEPMs is correlated with osteoblast differentiation in the midface. It is interesting to note that the distribution of *Pdgfra* mRNA expression compared to pAkt activity and AP staining is not strictly one-to-one; we speculate other factors such as ligand distribution, availability of intracellular signaling proteins, and input from other pathways may contribute toward the spatially restricted domains of osteoblast differentiation. We further observed elevated AP expression in *Fgfr1* conditional mutants at E14.5, consistent with FGF-mediated repression of osteoblast differentiation. Many functions have been ascribed to FGF signaling in skeletogenesis ([@bib42]), and a combination of parameters is likely responsible for the multiplicity of observed roles, such as ligand identity ([@bib18]) and cellular context. During palatogenesis, *Fgfr1* mutants have been previously reported to exhibit proliferation defects and increased BMP (Bone Morphogenetic Protein) signaling ([@bib60]), supporting the notion that FGF drives proliferation and represses differentiation in this system. In addition, the facial clefting phenotypes associated with neural crest conditional loss of RAF, MEK, or ERK ([@bib41]) suggest that the FGF-ERK axis is functionally relevant in vivo.

One important point merits further discussion: Are PI3K and ERK induction interpreted the same independently of the stimulus driving effector activity? There is evidence to suggest this is indeed the case, as IGF (Insulin-like growth factor 1)-mediated PI3K/Akt activation is a key regulator of osteoblast differentiation in mesenchymal stem cells ([@bib62]), consistent with the PI3K-mediated differentiation outcome in MEPMs. However, this interpretation is likely restricted in large part by cellular context, as MEK/ERK signaling functions as a positive regulator of differentiation in embryonic stem cells ([@bib64]), in contrast to the role of MEK/ERK signaling in MEPMs. In skeletal differentiation, our findings of a MEK/ERK-mediated proliferation program and PI3K-mediated differentiation program are in line with previous work analyzing the role of these effectors ([@bib34]; [@bib46]; [@bib38]). In addition, a FGF-PKC-AP-1 signaling axis in calvarial osteoblasts has been reported ([@bib37]), consistent with the MEPM data linking FGF to a robust AP-1 response and FGF-mediated pERK activation to PKC signaling. Delineating the hierarchy between these signals and pathways and determining the exact combinations sufficient to specify particular outcomes will be key questions for future studies. The present work provides a roadmap of the gene expression profiles underlying these cellular behaviors and a transcriptomic view of how two different RTKs lead to distinct outcomes.

Materials and methods {#s4}
=====================

Mouse strains {#s4-1}
-------------

All animal experiments were approved by the Institutional Animal Care and Use Committee at the Icahn School of Medicine at Mount Sinai. Wild-type C57B/6 mice were used to generate E13.5 MEPMs for RNA-seq. *Pdgfra*^*tm11(EGFP)Sor*^ ([@bib19]), referred to as *Pdgfra-GFP* in the text, were maintained on a C57BL/6 background, and *FGFR1-CFP* mice (to be described elsewhere), *FGFR1*^*tm5.1Sor*^ mice ([@bib21]), referred to as *Fgfr1*^*fl/fl*^ in the text, and *Tg(Wnt1-Cre)11Rth* mice ([@bib13]), referred to as *Wnt1-Cre* in the text, were all maintained on a 129S4 background.

Tissue culture {#s4-2}
--------------

Primary MEPM cells were isolated from E13.5 secondary palatal shelves (day of plug: E0.5) as previously described ([@bib16]; [@bib57]). Cells were grown in Dulbecco\'s modified Eagle's medium (GIBCO; Invitrogen, Carlsbad, CA) with 10% fetal bovine serum (FBS; HyClone Laboratories, Logan, UT), 50 U/mL penicillin (GIBCO), 50 μg/mL streptomycin (GIBCO), and 2 mM L-glutamine (GIBCO). Cells were split twice to passage 2 for all experiments included in this study, and serum starvation was conducted in same media as above but with 0.1% FBS instead of 10% FBS. BrdU assays ([@bib7]; [@bib57]) and AP staining ([@bib61]) were performed as described previously.

RNA-seq {#s4-3}
-------

Passage 2 E13.5 MEPMs were serum starved overnight in 0.1% FBS and then treated with either 30 ng/mL PDGFAA (R&D Systems, Minneapolis, MN) or 50 ng/mL FGF1 (Peprotech, Rocky Hill, NJ) + 1 μg/mL heparin (Sigma-Aldrich, St. Louis, MO) for the desired duration. When pathway inhibitors were used, cells were pretreated with either 1 μM PD325901 or 10 μM LY294002 for 30 min prior to growth factor addition. MEPMs generated from independent litters were used for each set of replicates, and RNA was collected using RNeasy Mini Kit (Qiagen Inc., Valencia, CA) according to manufacturer\'s protocol before submission to the Mount Sinai Genomics Core (<http://icahn.mssm.edu/departments-and-institutes/genomics/about/resources/genomics-core-facility>), where RNA was poly-A selected, libraries generated, and sequenced on Illumina HiSeq 2000. Between 25 and 40 million reads per sample were obtained and mapped to the mouse genome (version mm10) using TopHat ([@bib26]). Genes were tested for differential expression by Cuffdiff and considered significant at q \<0.1 ([@bib54]). Data for untreated, 1-hr PDGF, and 1-hr FGF treated MEPMs are publicly available at the Gene Expression Omnibus (GEO), Accession GSE61755 (42). Data for 4 hr PDGF, 4 hr FGF, 1 hr PDGF + PD325901, 1 hr PDGF + LY294002, 4 hr PDGF + PD325901, 4 hr PDGF + LY294002, 1 hr FGF + PD325901, 1 hr FGF + LY294002, 4 hr FGF + PD325901, and 4 hr FGF + LY294002 samples are publicly available at the GEO, Accession GSE66484.

RT-qPCR {#s4-4}
-------

E13.5 MEPMs were serum starved overnight in 0.1% FBS and then treated with desired growth factors and/or inhibitors as for RNA-seq. Total RNA was collected with the RNeasy Mini Kit (Qiagen Inc.). First-strand cDNA was then synthesized using a ratio of 2:1 random primers: Oligo(dT) with SuperScript II RT (Invitrogen). qPCR was performed using a Bio-Rad iQ5 Multicolor Real-Time PCR Detection System and analyzed with iQ5 Optical System Software (version 2.0; Bio-Rad, Hercules, CA). Reactions were performed with PerfeCTa SYBR Green FastMix for iQ (Quanta Biosciences Inc., Gaithersburg, MD) using 10 μM primers (Integrated DNA Technologies Inc., Coralville, IA). A list of qPCR primers used is available in [Supplementary File 5](#SD5-data){ref-type="supplementary-material"}. The following cycling protocol was used: step 1: 95°C for 3 min; step 2: 95°C for 10 s; step 3: 60° for 40 s; repeat to step 2 39× (total of 40 cycles), and a melting curve analysis was performed. In addition, PCR products were run on a 1.0% agarose gel to ensure correct amplicon size. *β2m* was used as an endogenous control.

Western blot {#s4-5}
------------

MEPMs were serum starved overnight and treated as for RNA-seq and then washed 3× in ice-cold PBS (Phosphate-buffered saline) before being harvested in NP-40 lysis buffer (20 mM Tris--HCl pH 8, 150 mM NaCl, 10%glycerol, 1% Nonidet P-40, 2 mM EDTA (Ethylenediaminetetraacetic acid), 1× complete Mini protease inhibitor cocktail \[Roche Applied Science, Indianapolis, IN\], 1 mM PMSF (Phenylmethanesulfonylfluoride), 10 mM NaF, 1 mM Na3VO4, and 25 mM β-glycerophosphate). Total cell lysates were sonicated briefly and then collected by centrifugation. Lysates were then resuspended in Laemmli buffer containing 10% β-mercaptoethanol, heated at 95°C for 5 min, and separated by SDS-polyacrylamide gel electrophoresis.

The following inhibitors were used: LY294002 (Sigma-Aldrich), PD325901 (Stemgent, Cambridge, MA), cycloheximide (Fisher Scientific, Waltham, MA), and Bim I (Santa Cruz Biotechnology, Dallas, TX).

The following antibodies were used: anti-phospho MAPK p42/p44 (9201; Cell Signaling Technologies, Danvers, MA; 1:1000), anti-pAkt (9271; Cell Signaling Technologies; 1:1000), and anti-pJNK (4671; Cell Signaling Technologies; 1:1000). The anti-β tubulin E7 antibody (1:1000) developed by M. Klymkowsky was obtained from the Developmental Studies Hybridoma Bank developed under the auspices of the NICHD and maintained by The University of Iowa, Department of Biology, Iowa City, IA.

Immunofluorescence {#s4-6}
------------------

Immunofluorescence was performed as described previously ([@bib57]). Briefly, cells were fixed in 4% formaldehyde at room temperature, blocked in 10% donkey serum, stained with primary antibody, and detected with secondary antibody, all for 1 hr at room temperature. The following antibodies were used: Anti-Cleaved Caspase-3 (CST9661; Cell Signaling Technology; 1:400). The anti-BrdU (G3G4, 1:500) developed by S. Kaufman was obtained from the Developmental Studies Hybridoma Bank, created by the NICHD of the NIH and maintained at The University of Iowa, Department of Biology, Iowa City, IA.

IHC {#s4-7}
---

IHC was performed as described previously ([@bib16]). For whole mounts, embryos were dissected onto ice-cold PBS, fixed overnight in 4:1 methanol:DMSO, cleared in 4:1:1 methanol:DMSO:H~2~O~2~, and stored in 100% methanol. For sections, embryos were fixed overnight in 4% paraformaldehyde (PFA) and embedded in paraffin. Staining was done with primary antibody overnight and a goat anti-rabbit IgG peroxidase-conjugated secondary antibody (Jackson ImmunoResearch Laboratories Inc., West Grove, PA). Detection was performed using the Vector Laboratories SK-4100 kit (Vector Laboratories Inc., Burlingame, CA).

In situ hybridization {#s4-8}
---------------------

Embryos were dissected in ice-cold PBS and fixed overnight in 4% PFA and embedded in paraffin or optimal cutting temperature compound for sectioning. In situ hybridization was performed according to standard protocols ([@bib20]; [@bib57]). A list of probe sequences is provided in [Supplementary File 5](#SD5-data){ref-type="supplementary-material"}.

Data analysis {#s4-9}
-------------

Generation of heatmaps, PCA, and other analysis were performed through custom code in R. PCA was done using the 'prcomp' function on centered, median normalized data, and correlation matrix was constructed using the 'cor' function on log~2~(FPKM + 1) transformed data. Hierarchical clustering and heatmaps were generated using the 'heatmap.2' and 'hclust' functions. Pearson\'s correlation was used in the correlation matrix, and Euclidean distance was used as a distance metric for hierarchical clustering. PPI networks were constructed using the Expression2Kinase software ([@bib9]) based on an updated version of Genes2Networks ([@bib4]), only direct connections (path length = 1) were considered, and all published PPI databases except predicted PPIs were included. Networks were visualized and formatted in yEd ([www.yworks.com](http://www.yworks.com/)). For Gene ontology analysis ([@bib22]), only those terms at a significance threshold of p \<0.001 were included. Redundant GO terms comprising an identical or fully shared subset of genes were removed. A full list of GO results is provided in [Supplementary File 4](#SD4-data){ref-type="supplementary-material"}.
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Thank you for sending your work entitled "Receptor tyrosine kinases modulate distinct transcriptional programs by differential usage of intracellular pathways" for consideration at *eLife*. Your article has been favorably evaluated by Fiona Watt (Senior editor), Marianne Bronner (Reviewing editor), and three reviewers.

The Reviewing editor and the reviewers discussed their comments before we reached this decision, and the Reviewing editor has assembled the following comments to help you prepare a revised submission.

In this study, the authors took advantage of palatal mesenchymal cells in which both FGF and PDGF signaling utilize receptor tyrosine kinase (RTK) to regulate downstream target genes during palatogenesis. To investigate the mechanisms underlying RTK specificity in craniofacial development, the authors performed detailed FGF and PDGF responsive gene analyses. They show that FGF signaling favors cell proliferation through activation of ERK whereas PDGF signaling mainly promotes cell differentiation through PI3K. Their results show that PDGF requires PI3K and affects differentiation while FGF depends on MEK/ERK and promotes proliferation. Furthermore although the FGF response was shown to be quantitatively stronger, there was considerable interconnectivity across the intracellular pathways which urges caution with respect to general effector inhibitor experiments and conclusions. The study is carefully done. Some further experimentation, described below, would strengthen the results.

1\) The interpretations seem too focussed on the differences in MEK and PI3K signaling as explaining the changes in transcription between 1h and 4h. For example, in the Results section it is concluded: "In sum, both RTKs induce a qualitatively similar gene expression program at 1 hour, but FGF drives a quantitatively stronger early response, resulting in divergent gene expression profiles at 4 hours." This seems to be jumping the gun, as much of the evidence comes later in the Results. What is meant by 'similar' gene expression programs at early stages? Perhaps there are some differences in early transcription factor expression that contribute to the greater divergence at 4h. A network of induced genes is shown in [Figure 1](#fig1){ref-type="fig"}, but are these the only ones? It would be useful to have a list of the differentially expressed genes at 1h, and some explicit discussion on this point.

2\) Although the PDGF-PI3K/Akt signaling axis and FGF-MEK/ERK signaling are known to be important for craniofacial development, this concern is outweighed by the novelty of the comparative systematic transcriptional analyses of PDGF and FGF signaling in the palatal mesenchyme under the same experimental conditions. Some deeper analyses of the respective *Fgfr1* or *Pdgfra* mutants (either null or conditional as appropriate) would strengthen the authors\' interpretations and conclusions in vivo. The RTK pathway intersection the authors observed in MEPM cells could easily be thoroughly validated in the background of the respective mutants.

3\) In the experiment where the authors inhibited pERK by using PD325901, the authors found activation of pJNK. It would be helpful to know if there are any changes in apoptotic activity in PD325901-treated MEPMs.

4\) In reviewing the *Pdgfra* expression pattern, it is clear that *Pdgfra* is localized throughout the palatal mesenchyme ([Figure 6B\'](#fig6){ref-type="fig"}) whereas the condensation of palatal mesenchyme and osteogenic differentiation is mainly located in the nasal region of the palatal shelf ([Figure 6B](#fig6){ref-type="fig"}). What is the functional significance of PDGF signaling in the oral region of the palatal shelf? Is PI3K activation only restricted to the nasal region where osteogenic differentiation will occur?

5\) The tissue orientation in [Figure 6C](#fig6){ref-type="fig"} is not clear. In general, palatal shelves should have fused at E14.5 in the control sample. Here, both control and *Fgfr1* mutant samples show that palatal shelves are blocked by the tongue.

10.7554/eLife.07186.020

Author response

*1) The interpretations seem too focussed on the differences in MEK and PI3K signaling as explaining the changes in transcription between 1h and 4h. For example, in the Results section it is concluded: "In sum, both RTKs induce a qualitatively similar gene expression program at 1 hour, but FGF drives a quantitatively stronger early response, resulting in divergent gene expression profiles at 4 hours." This seems to be jumping the gun, as much of the evidence comes later in the Results. What is meant by 'similar' gene expression programs at early stages? Perhaps there are some differences in early transcription factor expression that contribute to the greater divergence at 4h. A network of induced genes is shown in* [*Figure 1*](#fig1){ref-type="fig"}*, but are these the only ones? It would be useful to have a list of the differentially expressed genes at 1h, and some explicit discussion on this point*.

We agree that a more thorough discussion of the transcription factor changes observed at 1 hour is warranted. By 'similar' gene expression programs, we are referring to the high correlation coefficient between the fold change of differentially regulated genes at 1 hour for both PDGF and FGF treatment, as plotted in [Figure 1C](#fig1){ref-type="fig"}, compared to the correlation at 4 hours, as plotted in [Figure 1C\'](#fig1){ref-type="fig"}. Further, the set of PDGF targets at 1 hour are a subset of FGF targets at 1 hour (i.e. all PDGF targets at 1 hour are also identified as significantly regulated FGF targets by Cuffdiff, although the kinetics and magnitude of regulation are different). The main text has been amended in the Results section to make these points explicit. In addition, of the 34 total transcription factors identified within the FGF target gene list at 1 hour, 76% (26/34) are also significantly regulated by PDGF stimulation ([Supplementary file 4](#SD4-data){ref-type="supplementary-material"}), again underscoring the high degree of overlap at the early timepoint.

We do concur with the reviewers\' point that quantitative differences in the early transcriptional response (which is shared across both PDGF and FGF stimulation) likely contribute to the divergence at 4 hours. Indeed, there exist examples in which the magnitude and duration of IEG induction can specify distinct late responses (Murphy, LO, et al. Nat. Cell Biology. 4, 556-564, 2002 and Nakakuki, T. et al. Cell. 141, 884--896, 2010). We accordingly altered our statement in the Results section, as the reviewers rightly indicate much of the data comes later in the manuscript, and we further added a few sentences in the Discussion summarizing the likely importance of distinct transcription factor induction patterns (in addition to MEK/ERK and PI3K dependence) to explain the observed differences at 4 hours.

In the presented PPI network ([Figure 1D](#fig1){ref-type="fig"}), 25 of the 113 genes significantly upregulated at 1 hour are depicted, and this statement has been added to the main text (Results section). A full list of these genes can be found in [Supplementary file 2](#SD2-data){ref-type="supplementary-material"}, Columns A-H on the sheet entitled 'ComparedToUntreated.'

*2) Although the PDGF-PI3K/Akt signaling axis and FGF-MEK/ERK signaling are known to be important for craniofacial development, this concern is outweighed by the novelty of the comparative systematic transcriptional analyses of PDGF and FGF signaling in the palatal mesenchyme under the same experimental conditions. Some deeper analyses of the respective Fgfr1 or Pdgfra mutants (either null or conditional as appropriate) would strengthen the authors\' interpretations and conclusions in vivo. The RTK pathway intersection the authors observed in MEPM cells could easily be thoroughly validated in the background of the respective mutants*.

We agree that in vivo validation of our observations in MEPMs is highly desirable. Neither Pdgfra (Soriano, P. Development. 124, 2691-2700, 1997) nor Fgfr1 (Deng, CX. et al. Genes and Dev. 8, 3045-3057, 1994. and Yamaguchi, TP. et al. Genes and Dev. 8, 3032-3044, 1994) null mutants are recovered at Mendelian ratios at E13.5. Thus, we carried out RT-qPCR analysis in E13.5 secondary palates isolated from Wnt1-Cre; Pdgfra^fl/fl^ and Wnt1-Cre; Fgfr1^fl/fl^ neural crest conditional mutants ([Author response image 1](#fig7){ref-type="fig"}).10.7554/eLife.07186.021Author response image 1.Expression of PDGF and FGF target genes in Pdgfra (red) and Fgfr1 (blue) mutant E13.5 secondary palates compared to control embryos without the Wnt1-Cre transgene (black). \*p \< 0.1; \*\*p \< 0.01, n = 4 for each genotype.**DOI:** [http://dx.doi.org/10.7554/eLife.07186.021](10.7554/eLife.07186.021)

The expression of IEGs such as Fos and Jun is unchanged, an expected result given the number of stimuli capable of inducing these genes as well as the observation that both PDGF and FGF treatment can induce these genes in MEPMs. Many differentiation genes (Mef2c, Alx1, Alx4, and Alpl) exhibit significantly greater expression in Fgfr1 mutants compared to Pdgfra mutants or control embryos, consistent with the MEPM data in which these genes display greater expression at 4 hours following PDGF treatment compared to 4 hours following FGF treatment. However, the Id genes (Id1, Id2, and Id3) do not conform to this trend and have similar expression across all genotypes; this may be due to compensation in vivo, particularly by BMP signaling, a canonical inducer of Id gene expression. Finally, it is interesting to note a high level of residual Pdgfra and Fgfr1 expression in the corresponding mutants. We believe this reflects receptor expression from non-neural crest derived contributions to the secondary palate (such as the mesoderm). Indeed, when we performed in situ hybridization for Pdgfra in Wnt1-Cre; Pdgfra^fl/fl^ mutants and Fgfr1 expression in Wnt1-Cre; Fgfr1^fl/fl^ mutants, we found some receptor mRNA expression in the E13.5 palate of the respective conditional mutants (data not shown), consistent with our qPCR results. Furthermore, flow cytometry analysis of PDGFRα expression in 10.5 branchial arches of Wnt1-Cre; Pdgfra^fl/fl^ conditional mutants revealed no receptor expression, indicating satisfactory deletion by the Wnt1-Cre transgene in early structures derived from the neural crest (Tallquist, MD, and Soriano, P. Development. 130, 507-518, 2003). Finally, the same qPCR primers, when used to measure Pdgfra and Fgfr1 expression in E11.5 facial prominences isolated from the respective conditional mutants, revealed almost complete loss of these genes, thus suggesting the observed residual expression is likely not a technical issue associated with the qPCR protocol itself (Vasudevan, HN, and Soriano, P. Dev. Cell. 31, 332-344, 2014).

In summary, although we do observe supportive trends for a number of differentiation genes (Mef2c, Alx1, Alx4, and Alpl), results are mixed for other targets, which may be explained by compensation in vivo, residual receptor expression, or other factors. The development of Cre drivers more precise than the Wnt1-Cre that drive recombination within the secondary palate itself (rather than in the early neural crest) would facilitate the in vivo validation of the observations made in MEPMs. We believe the generation of such tools and subsequent analysis of Pdgfra and Fgfr1 mutants, while certainly important, is outside the scope of this study. We chose not to include the in vivo data obtained from the Wnt1-Cre mutant palatal shelves in the main text, as the observed residual receptor expression precludes clear interpretation of these results.

*3) In the experiment where the authors inhibited pERK by using PD325901, the authors found activation of pJNK. It would be helpful to know if there are any changes in apoptotic activity in PD325901-treated MEPMs*.

We have performed the suggested experiment and measured apoptosis using cleaved caspase-3 (CC3) for FGF and PDGF treated MEPMs in the presence and absence of both PD325901 (MEK inhibitor) and LY294002 (PI3K inhibitor) ([Figure 5---figure supplement 1D](#fig5s1){ref-type="fig"}). In the case of FGF treatment, both MEK and PI3K inhibition increase the percentage of CC3+ cells, but MEK inhibition has a significantly greater effect, consistent with the induction of pJNK in this condition ([Figure 4A](#fig4){ref-type="fig"}). In contrast, PI3K inhibition has a greater effect on apoptosis in PDGF treated cells, and again, both inhibitors show significantly increased apoptosis compared to PDGF treated cells alone. This result is not wholly surprising given the modest pJNK induction in the LY294002 dose response curve for PDGF treated cells ([Figure 4B\'](#fig4){ref-type="fig"}). In addition, both PD325901 and LY294002 are known to induce apoptosis in other cell types, and our results suggest intracellular signaling in response to FGF and PDGF stimulation exhibit different sensitivities to the apoptotic effect of these inhibitors. The CC3 measurements are generally consistent with the crystal violet assay, where FGF exhibits greater MEK dependence while PDGF-mediated effects on cell viability are sensitive to both MEK and PI3K inhibition ([Figure 5---figure supplement 1C](#fig5s1){ref-type="fig"}). We have added this result in [Figure 5---figure supplement 1D](#fig5s1){ref-type="fig"} and removed the schematic of RTK mediated control of cell proliferation and differentiation, as a similar model is presented in [Figure 6D](#fig6){ref-type="fig"}. We have included a line in the main text describing these apoptosis results (please see the subsection headed "FGF drives MEK/ERK-dependent cell proliferation, and PDGF promotes PI3K-dependent cell differentiation").

*4) In reviewing the Pdgfra expression pattern, it is clear that Pdgfra is localized throughout the palatal mesenchyme (*[*Figure 6B\'*](#fig6){ref-type="fig"}*) whereas the condensation of palatal mesenchyme and osteogenic differentiation is mainly located in the nasal region of the palatal shelf (*[*Figure 6B*](#fig6){ref-type="fig"}*). What is the functional significance of PDGF signaling in the oral region of the palatal shelf? Is PI3K activation only restricted to the nasal region where osteogenic differentiation will occur?*

The reviewers astutely observe that Pdgfra mRNA expression is evenly distributed, which leads to a question regarding the spatial distribution of Pdgfra mRNA expression, PI3K activation, and osteogenic differentiation in the palate. Regarding PI3K activation, it is important to note that our immunohistochemistry results identify regions of relative enrichment for pAkt and may not reflect an absolute lack of pAkt in regions that appear negative. In addition, PI3K can signal through Akt independent pathways, and it is possible PI3K activation recruits these other pathways outside the observed pAkt domains. While Pdgfra mRNA expression is ubiquitous throughout the palatal mesenchyme, receptor expression level, ligand distribution, or availability of intracellular signaling proteins may all affect the extent and function of PDGF signaling in different regions. It is also possible that PDGF signaling is necessary but not sufficient for PI3K activation and osteogenic differentiation. In this scenario, the spatially restricted patterns of pAkt induction and osteogenic differentiation may function as coincidence detectors that respond only to the coordinate activation of multiple signals. We have added a line in the Discussion mentioning these possibilities. One approach to unambiguously determine the functional role of PDGFRα in the oral region could involve the use of a spatially specific Cre driver, but the tools to perform such an analysis are currently lacking.

*5) The tissue orientation in* [*Figure 6C*](#fig6){ref-type="fig"} *is not clear. In general, palatal shelves should have fused at E14.5 in the control sample. Here, both control and Fgfr1 mutant samples show that palatal shelves are blocked by the tongue*.

The reviewers raise a concern regarding the time of palatal fusion in mouse development. In our mice, which are maintained on a 129S4 background, secondary palate fusion is not complete at E14.5 (see also Fantauzzo, KA, and Soriano, P. Genes Dev. 28, 1005--1017, 2014). This is also consistent with previous observations made with SEM (Kaufman. The Atlas of Mouse Development. 426-429, 1992) and H/E staining (Bush, JO, and Jiang, R. Development 139, 828--828, 2012). However, it is intriguing to note that other databases, such as FaceBase depict contact between the palatal shelves at E14.5 (<https://www.facebase.org/sites/default/files/SEM_images/anatomy.html>). We suspect this discrepancy in the exact time of secondary palate fusion may be background dependent, as FaceBase uses C57BL/6 embryos. Regarding the sections from Fgfr1 mutant palatal shelves, we have replaced the original image with a lower magnification image from a different embryo ([Figure 6C](#fig6){ref-type="fig"}) to better orient the reader and have clarified in the figure legend that these are frontal sections.
